Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis.
Roman FischerMarcel ProskeMaëlle DuffeyHubert StanglGeorge F MartinezNathalie PetersAlexandra KraskeRainer H StraubJohn R BetheaRoland E KontermannKlaus PfizenmaierPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
Our findings support the use of TNFRII-selective therapeutics as an effective approach to the treatment of arthritic disease and possibly other inflammatory and autoimmune diseases.